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Abstract
Background
There are conflicting reports regarding the association of the macrolide antibiotic clarithro-
mycin with cardiovascular (CV) events. A possible explanation may be that this risk is partly
mediated through drug–drug interactions and only evident in at-risk populations. To the best
of our knowledge, no studies have examined whether this association might be mediated
via P-glycoprotein (P-gp), a major pathway for clarithromycin metabolism. The aim of this
study was to examine CV risk following prescription of clarithromycin versus amoxicillin and
in particular, the association with P-gp, a major pathway for clarithromycin metabolism.
Methods and findings
We conducted an observational cohort study of patients prescribed clarithromycin or amoxi-
cillin in the community in Tayside, Scotland (population approximately 400,000) between 1
January 2004 and 31 December 2014 and a genomic observational cohort study evaluating
genotyped patients from the Genetics of Diabetes Audit and Research Tayside Scotland
(GoDARTS) study, a longitudinal cohort study of 18,306 individuals with and without type
2 diabetes recruited between 1 December 1988 and 31 December 2015. Two single-
nucleotide polymorphisms associated with P-gp activity were evaluated (rs1045642 and
rs1128503 –AA genotype associated with lowest P-gp activity). The primary outcome for
both analyses was CV hospitalization following prescription of clarithromycin versus amoxi-
cillin at 0–14 days, 15–30 days, and 30 days to 1 year. In the observational cohort study,
we calculated hazard ratios (HRs) adjusted for likelihood of receiving clarithromycin using
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inverse proportion of treatment weighting as a covariate, whereas in the pharmacogenomic
study, HRs were adjusted for age, sex, history of myocardial infarction, and history of
chronic obstructive pulmonary disease.
The observational cohort study included 48,026 individuals with 205,227 discrete antibi-
otic prescribing episodes (34,074 clarithromycin, mean age 73 years, 42% male; 171,153
amoxicillin, mean age 74 years, 45% male). Clarithromycin use was significantly associated
with increased risk of CV hospitalization compared with amoxicillin at both 0–14 days (HR
1.31; 95% CI 1.17–1.46, p < 0.001) and 30 days to 1 year (HR 1.13; 95% CI 1.06–1.19, p <
0.001), with the association at 0–14 days modified by use of P-gp inhibitors or substrates
(interaction p-value: 0.029). In the pharmacogenomic study (13,544 individuals with 44,618
discrete prescribing episodes [37,497 amoxicillin, mean age 63 years, 56% male; 7,121
clarithromycin, mean age 66 years, 47% male]), when prescribed clarithromycin, individuals
with genetically determined lower P-gp activity had a significantly increased risk of CV hospi-
talization at 30 days to 1 year compared with heterozygotes or those homozygous for the
non-P-gp–lowering allele (rs1045642 AA: HR 1.39, 95% CI 1.20–1.60, p < 0.001, GG/GA:
HR 0.99, 95% CI 0.89–1.10, p = 0.85, interaction p-value < 0.001 and rs1128503 AA 1.41,
95% CI 1.18–1.70, p < 0.001, GG/GA: HR 1.04, 95% CI 0.95–1.14, p = 0.43, interaction p-
value < 0.001). The main limitation of our study is its observational nature, meaning that we
are unable to definitively determine causality.
Conclusions
In this study, we observed that the increased risk of CV events with clarithromycin compared
with amoxicillin was associated with an interaction with P-glycoprotein.
Author summary
Why was this study done?
• Macrolide antibiotics such as clarithromycin are frequently used for treatment of lower
respiratory tract infections.
• Several studies have reported increased cardiovascular risk associated with clarithromy-
cin prescription, including the Effect of Clarithromycin on Mortality and Morbidity in
Patients With Ischemic Heart Disease (CLARICOR) randomized-controlled trial.
• The mechanism behind this increased risk is unclear; however, it would be important to
identify patients who might be at higher risk when prescribed clarithromycin in whom
alternative antibiotics such as amoxicillin could be used.
What did the researchers do and find?
• We conducted an observational study in 2 parts to examine the association between
clarithromycin prescription and cardiovascular outcome.
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• First, we performed a propensity-weighted observational population cohort analysis
comparing clarithromycin versus amoxicillin prescription and cardiovascular outcome
in patients in Tayside, Scotland.
• In this analysis, we found that that patients prescribed clarithromycin were significantly
more likely to have a cardiovascular hospitalization at 0–14 days and 30 days to 1 year
after prescription than those prescribed amoxicillin and that individuals who were co-
prescribed P-glycoprotein substrates or inhibitors and clarithromycin had a signifi-
cantly higher risk of cardiovascular hospitalization.
• To explore these findings further, we performed a pharmacogenomic study involving
patients with available genotype data from the Genetics of Diabetes Audit and Research
Tayside Scotland (GoDARTS) study.
• Using 2 genetic variants associated with P-glycoprotein activity (rs1045642 and
rs1128503), we found that patients with the AA genotype, which for both variants is
associated with reduced P-glycoprotein activity, had a significantly increased risk of car-
diovascular hospitalization between 30 days and 1 year.
What do these findings mean?
• Our findings raise the possibility that the observed association between clarithromycin
prescription and increased cardiovascular risk could be mediated by P-glycoprotein.
• These results may have implications for clarithromycin use in patients taking P-glyco-
protein inhibitors or with low genetically predicted P-glycoprotein activity.
Introduction
Clarithromycin is a widely prescribed macrolide antibiotic, comprising around 15% of all pri-
mary care antibiotic prescriptions in the United Kingdom, recommended for treatment of
patients with lower respiratory tract infections either as monotherapy or in combination [1–
3]. There has been growing concern regarding increased cardiovascular (CV) risk of clarithro-
mycin. The Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic
Heart Disease (CLARICOR) trial in patients with high CV risk [4], designed to test the hypoth-
esis that clarithromycin would reduce CV risk, actually found that 2 weeks of clarithromycin
caused a 45% relative risk increase in CV mortality compared with placebo. These results were
supported by a number of observational studies [5–8] and meta-analyses [9, 10] suggesting
that clarithromycin and other macrolide antibiotics were associated with adverse outcome, not
only in the short term during and after exposure, but also in the longer term after drug discon-
tinuation, leading to a recent United States Food and Drug Administration (FDA) safety alert
on the use of clarithromycin in patients with heart disease [11, 12]. Nonetheless, recently,
studies in lower-risk community populations have not found this association. An emerging
hypothesis is that these conflicting results suggest that the high CV risk with clarithromycin
may only be present in a subset of individuals [13–16].
A potential risk modifier is concurrent medication use. Clarithromycin is both a substrate
and inhibitor of both cytochrome p4503A4 (CYP3A4) [17] and permeability-glycoprotein (P-
gp) [18], meaning that circulating clarithromycin levels are affected by alterations in CYP3A4
PLOS MEDICINE P-Glycoprotein, clarithromycin, and cardiovascular risk
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or P-gp activity [19]. Several studies have investigated the possibility of an interaction between
clarithromycin, concomitant CYP3A4 medication use, and CV risk; however, no robust asso-
ciation has been found [6, 14, 20]. To the best of our knowledge, there have been no original
research studies evaluating whether the association between clarithromycin use and CV risk
is modulated via P-gp. Both animal [19] and clinical studies [21, 22] suggest that co-adminis-
tration of P-gp inhibitors such as verapamil, omeprazole, nelfinavir [23], or ketoconazole
with macrolide antibiotics leads to an increase in the oral bioavailability of macrolides and
increased plasma levels. Further support for an interaction between P-gp inhibition and
macrolides comes from genetic studies showing that patients with genetic variants associated
with low P-gp activity also have higher levels of macrolides when exposed to these antibiotics
[24]. The use of pharmacogenomics may help overcome some of the limitations of observa-
tional studies and help shed light on potential drug interactions.
We hypothesized that the increased CV risk associated with clarithromycin may be linked
with concurrent use of P-gp inhibitors or substrates and that individuals with genotypes asso-
ciated with low P-gp activity, a proxy for P-gp inhibition, would also have an increased CV
risk when prescribed clarithromycin.
Methods
The study consisted of 2 parts: a traditional observational cohort study and a pharmacogeno-
mic study.
Observational cohort study
The prospective analysis plan for this section of the study can be found in S1 Text. The study
population was all approximately 400,000 residents of the Tayside region of Scotland regis-
tered with an NHS Tayside general practice at any point in the study period (2004–2014).
Demographic and community prescribing data were obtained through the Health Informatics
Centre (HIC), University of Dundee, which provides anonymized linked individual patient
data, including prescribing of antibiotics as previously described [25]. These datasets were
linked to other datasets including demographic, clinical, hospital admission, and mortality
data that are linked by a unique 10-digit patient identifier (the Community Health Index num-
ber) used for all healthcare activities in Scotland. All research data are robustly anonymized
and approved by the Tayside National Health Service Caldicott Guardian under an overarch-
ing ethical approval for anonymized data research using HIC. Prescribing data between 2004
and 2014 were used to identify all patients over 18 years old who were prescribed clarithromy-
cin (alone or in combination with amoxicillin or another antibiotic) over this period. A control
group of individuals prescribed amoxicillin as a sole antibiotic was also identified. A propen-
sity-score model for clarithromycin exposure was estimated using baseline demographic
and clinical covariates hypothesized to be relevant shown in Table 1. Outcome models were
weighted using inverse propensity of treatment weights (IPTWs) to account for baseline differ-
ences between exposure cohorts and robust sandwich covariance estimation to account for
multiple exposures for each individual.
Pharmacogenomic cohort study: Association of genetically determined P-
gp activity, clarithromycin, and CV mortality
We did not have a prespecified analysis plan for the pharmacogenomic study; however, the
analysis was informed by the observational cohort study. Patients with available prescribing
data were obtained from the Genetics of Diabetes Audit and Research in Tayside Scotland
study (GoDARTS), the details of which have been published previously [26]. In brief, this is a
PLOS MEDICINE P-Glycoprotein, clarithromycin, and cardiovascular risk
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longitudinal cohort study comprising 18,306 individuals, 10,149 with type 2 diabetes (T2D)
and 8,157 controls without T2D at the time of recruitment, of which genotype data were avail-
able for 8,564 T2D individuals and 4,586 controls. Genotyping data have been previously
described in full [26]. A blood sample for genotyping was obtained from individuals at base-
line, and all patients consented to electronic record linkage, allowing details on prescriptions
from 1989 to present and outcome data on deaths and hospitalizations. In this part of the
study, we again only included individuals who had received a prescription for either amoxicil-
lin or clarithromycin. Collection and analysis of data in GoDARTS was approved by the East
of Scotland Research and Ethics Committee. All participants had given written consent for
their data to be linked and analyzed for research purposes.
We selected 2 single-nucleotide polymorphisms (SNPs) within the human multidrug-resis-
tance MDR1 gene (ABCB1), which codes for P-gp, which have been shown to be associated
with P-gp activity in white healthy volunteers and for which there was a reasonably high preva-
lence of each genotype—rs1045642, rs1128503 [27–31]. Patients were categorized into 2
groups based on genotype with those individuals homozygous for the risk allele (the allele
associated with reduced P-gp activity—A for both SNPs), i.e., individuals with low genetically
predicted P-gp activity compared with heterozygous individuals and those homozygous for
the nonrisk allele (i.e., intermediate and high genetically determined P-gp activity).
Table 1. Baseline characteristics of observational cohort study.
Clarithromycin Amoxicillin Standardized Difference
Total Number of Unique Patients 11,489 36,537
Total Number of Prescriptions 34,074 171,153
Age at Prescription (years) [mean ± SD] 73.3 ± 12.3 74.2 ± 13.2 0.070
Male 14,280 (41.9) 76,521 (44.7) 0.056
Type 2 Diabetes 5,555 (16.3) 27,942 (16.3) <0.001
Chronic Obstructive Pulmonary Disease 8,647 (25.4) 25,282 (14.8) 0.267
Prior Myocardial Infarction 1,289 (3.8) 7,888 (4.6) 0.040
Prior Heart Failure 1,111 (3.3) 6,433 (3.8) 0.027
Clinically Indicated Echocardiography within previous year 3,151 (9.2) 13,913 (8.1) 0.039
History of Left Ventricular Systolic Impairment 359 (1.1) 1,743 (1.0) 0.010
Angiotensin Converting Enzyme Inhibitor 11,583 (34.0) 62,533 (36.5) 0.052
Angiotensin II Receptor Blocker 167 (0.5) 950 (0.6) 0.014
Aspirin 14,660 (43.0) 79,532 (46.4) 0.068
Beta Blocker 7,505 (22.0) 48,197 (28.2) 0.141
Clopidogrel 3,621 (10.6) 17,316 (10.1) 0.016
Dihydropyridine Calcium Channel Blocker 8,661 (25.4) 47,993 (28.0) 0.059
Loop Diuretic 15,292 (44.9) 66,654 (38.9) 0.122
Mineralocorticoid Receptor Antagonist 3,099 (9.1) 14,140 (8.3) 0.028
Nondihydropyridine Calcium Channel Blocker 527 (1.5) 2,547 (1.5) <0.001
Statin 14,105 (41.4) 76,308 (44.6) 0.065
Thiazide Diuretic 7,678 (22.5) 42,877 (25.0) 0.059
Warfarin 3,620 (10.6) 20,217 (11.8) 0.038
CYP3A4 inhibitor/substrate 7,902 (23.2) 31,664 (18.5) 0.116
P-glycoprotein inhibitor/substrate 15,080 (44.2) 78,285 (45.7) 0.030
Nonsteroidal anti-inflammatory drug 21,973 (64.5) 112,831 (65.9) 0.029
Figures represent mean ± SD or number with percentage in parentheses. Percentages are reported as a proportion of the number of prescriptions. CYP3A4, cytochrome
p4503A4.
https://doi.org/10.1371/journal.pmed.1003372.t001
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Study endpoints
The primary endpoint for both studies was CV hospitalization. In our initial funding proposal,
we planned to evaluate CV mortality as the primary endpoint; however, we felt we would be
likely to be underpowered based on the number of patients and changed this to CV hospitali-
zation before the preliminary analysis. Following the date of prescription, patients were fol-
lowed up for CV hospitalizations, myocardial infarction, and death based on International
Classification of Diseases (ICD)-10 coding for 1 year. The following codes were used: CV hos-
pitalization or death –I00-I99; myocardial infarction—I21, I22, and I23. As previous studies
have suggested that the CV risk may be different in the short term versus longer time periods,
we stratified outcomes at 0–14 days, 15–30 days, and 30 days to 1 year post-prescription. Fol-
lowing the 1-year period of follow-up post-prescription, or after a censored event, surviving
patients could be re-entered into the study if they had a further prescription of either antibi-
otic, similar to the methodology used in other large studies of this type [8, 32].
Statistical analysis
Continuous variables are reported as mean ± standard deviation, and categorical variables are
reported as number and percentage. Standardized mean differences (SMDs) between the clari-
thromycin and amoxicillin groups are reported, with an SMD > 0.1 considered a significant
difference between the groups.
In the observational cohort study, Cox proportional hazards regression was performed
for the outcome of CV hospitalization or hospitalization for MI at 0–14 days, 15–30 days, and
30 days to 1 year. Additionally, we evaluated the endpoints of all-cause and CV mortality.
Adjusted HRs in the observational study are reported adjusting for the IPTW, using the pro-
pensity score for likelihood of prescription of clarithromycin based on baseline variables
reported in Table 1 [33]. Analysis for the pharmacogenomic study was informed by the design
and results of the observational study. In the pharmacogenomic study, a multivariable Cox
regression analysis was performed for the association between clarithromycin use versus
amoxicillin on CV hospitalization with adjustment for age at the time of antibiotic prescrip-
tion, sex, history of prior myocardial infarction (MI), chronic obstructive pulmonary disease
(COPD), and T2D. Interaction testing was performed to determine whether there was a signif-
icant difference between amoxicillin and clarithromycin prescribing depending on P-gp activ-
ity. All tests were 2-sided. Statistical analysis was performed using SAS (version 9.4, SAS
Institute, https://www.sas.com/en_gb/software/stat.html), STATA (version 14.0, StataCorp,
https://www.stata.com/), and R (version 3.5.1, The R Project for Statistical Computing, https://
www.r-project.org/).
This study is reported as per the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guideline (S1 Checklist).
Results
Observational longitudinal cohort study
Baseline characteristics. Over the duration of the study, there were 34,074 prescriptions
for clarithromycin for 11,489 unique individuals and 171,153 amoxicillin prescriptions for
36,537 unique individuals. The mean age at prescription was 73.3 ± 12.3 (mean ± standard
deviation) years in the clarithromycin group, and 41.9% were male, whereas in the amoxicillin
group, the mean age was 74.2 ± 13.2 years, and 44.7% were male. Baseline characteristics are
summarized in Table 1. Overall, individuals prescribed clarithromycin more likely to have
PLOS MEDICINE P-Glycoprotein, clarithromycin, and cardiovascular risk
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COPD and be prescribed loop diuretics and CYP3A4 inhibitors or substrates and were less
likely to be taking beta-blockers (SMD > 0.1).
Clinical Outcomes. Clinical outcomes of CV hospitalization, hospitalization for MI, CV
mortality, and all-cause mortality at 0–14 days, 15–30 days, and 30 days to 1 year are summa-
rized in Table 2. Within the first 14 days following clarithromycin prescription, there were 559
CV hospitalizations (1.6% of all prescriptions) and 289 deaths from any cause, compared with
the amoxicillin group in which there were 2,355 CV hospitalizations (1.2% of all prescriptions)
and 1,601 deaths from any cause.
In our propensity-weighted analysis, despite there being a higher number of absolute events
in the amoxicillin group, clarithromycin use was significantly associated with an increased
risk of CV hospitalization compared with amoxicillin only at both 0–14 days (unadjusted abso-
lute risk 1.6% versus 1.4%; propensity-weighted hazard ratio (HR) 1.31; 95% CI 1.17–1.46,
p< 0.001) and 30 days to 1 year (unadjusted absolute risk 1.3% versus 1.2%; propensity-
weighted HR 1.13; 95% CI 1.06–1.19, p< 0.001) but not at 15–30 days (unadjusted absolute
risk 5.4% versus 6.6%; propensity-weighted HR 1.11; 95% CI 0.98–1.26, p = 0.09) (Table 3). A
Table 2. Clinical outcomes in the observational cohort study (unadjusted counts and percentages).
Clarithromycin (n = 34,074) Amoxicillin (n = 171,153)
Cardiovascular Hospitalization 0–14 Days 559 (1.6) 2,355 (1.4)
15–30 Days 431 (1.3) 2,105 (1.2)
30 Days–1 Year 1,828 (5.4) 11,321 (6.6)
Hospitalization for MI 0–14 Days 34 (0.1) 169 (0.1)
15–30 Days 23 (0.07) 131 (0.08)
30 Days–1 Year 164 (0.5) 1,076 (0.6)
Cardiovascular Mortality 0–14 Days 73 (0.2) 532 (0.3)
15–30 Days 69 (0.2) 558 (0.3)
30 Days–1 Year 508 (1.5) 3,925 (2.3)
All-Cause Mortality 0–14 Days 289 (0.8) 1,601 (1.0)
15–30 Days 277 (0.8) 1,722 (1.0)
30 days–1 Year 1,530 (4.5) 9,991 (5.8)
Figures in parentheses refer to the number of events as a percentage of the total number of prescriptions. MI, myocardial infarction
https://doi.org/10.1371/journal.pmed.1003372.t002
Table 3. Association of clarithromycin and cardiovascular risk versus amoxicillin in the observational study.
0–14 Days 15–30 Days 30 Days–1 Year
Outcome Crude Hazard
Ratio (95% CI)
Adjusted Hazard
Ratio (95% CI)
p-value Crude Hazard
Ratio (95% CI)
Adjusted Hazard
Ratio (95% CI)
p-
value
Crude Hazard
Ratio (95% CI)
Adjusted Hazard
Ratio (95% CI)
p-value
Cardiovascular
Hospitalization
1.22 (1.10–1.34) 1.31 (1.17–1.46) <0.001 1.08 (0.97–1.21) 1.11 (0.98–1.26) 0.09 1.05 (1.00–1.11) 1.13 (1.06–1.19) <0.001
Hospitalization for
Myocardial Infarction
1.04 (0.72–1.49) 1.37 (0.89–2.11) 0.16 0.89 (0.57–1.40) 0.94 (0.54–1.62) 0.82 1.00 (0.84–1.18) 1.02 (0.85–1.24) 0.82
Cardiovascular
Mortality
0.85 (0.77–0.93) 0.93 (0.81–1.06) 0.25 0.66 (0.51–0.85) 0.82 (0.62–1.10) 0.18 0.85 (0.71–1.01) 0.96 (0.87–1.07) 0.46
All-Cause Mortality 0.86 (0.77–0.96) 1.05 (0.92–1.20) 0.43 0.80 (0.71–0.90) 0.93 (0.81–1.06) 0.25 0.95 (0.91–1.00) 0.97 (0.92–1.02) 0.18
p-values were estimated using robust covariance sandwich estimation and refer to the adjusted hazard ratio, which was adjusted using the likelihood of clarithromycin
prescription as a covariate (inverse probability of treatment weighting). This included the following variables: age at prescription, sex, prior history of chronic
obstructive pulmonary disease, prior myocardial infarction, history of type 2 diabetes, left ventricular systolic function impairment, and all medications listed in Table 1.
CI, confidence interval
https://doi.org/10.1371/journal.pmed.1003372.t003
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higher proportion of those taking clarithromycin had MI requiring hospitalization within 14
days, though this difference was not statistically significant (adjusted HR 1.37; 95% CI 0.89–
2.11, p = 0.12). There was no significant difference in all-cause or CV mortality between clari-
thromycin and amoxicillin at any time point.
When stratified by baseline clinical characteristics, the only significant interaction with
clarithromycin use and the primary outcome was in patients with a concomitant prescription
for medications metabolized through P-gp (Figs 1 and 2, unadjusted results in S1 Table).
Patients prescribed clarithromycin who were also taking P-gp inhibitors were significantly
more likely to have a CV hospitalization within the first 14 days (HR 1.97; 95% CI 1.16–3.36),
Fig 1. Subgroup analysis of risk of CV hospitalization at 14 days associated with clarithromycin use versus
amoxicillin. Hazard ratio adjusted using the likelihood of clarithromycin prescription as a covariate (inverse
probability of treatment weighting)—this included the following variables: age at prescription, sex, prior history of
COPD, prior MI, history of type 2 diabetes, left ventricular systolic function impairment, and all medications listed in
Table 1. CI, confidence interval; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; CYP3A4,
cytochrome P450 3A4; HF, heart failure; MI, myocardial infarction; PGP, P-glycoprotein.
https://doi.org/10.1371/journal.pmed.1003372.g001
Fig 2. Risk of CV hospitalization at 14 days stratified by concomitant P-glycoprotein medication prescription.
Hazard ratio adjusted using the likelihood of clarithromycin prescription as a covariate (inverse probability of
treatment weighting)—this included the following variables: age at prescription, sex, prior history of chronic
obstructive pulmonary disease, prior myocardial infarction, history of type 2 diabetes, left ventricular systolic function
impairment, and all medications listed in Table 1. CCB, calcium channel blocker; CI, confidence interval; CV,
cardiovascular.
https://doi.org/10.1371/journal.pmed.1003372.g002
PLOS MEDICINE P-Glycoprotein, clarithromycin, and cardiovascular risk
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whereas in those who were not taking P-gp inhibitors, there was no significant increase in
CV hospitalization with use of clarithromycin versus amoxicillin (HR 1.43; 95% CI 0.90–2.26,
interaction p-value 0.029). This interaction was not seen at 15–30 days or 30 days to 1 year
(15–30 days: P-gp, HR 0.93, 95% CI 0.49–1.76; no P-gp, HR 0.98, 95% CI 0.56–1.71, interac-
tion p value 0.74; 30 days–1 year: P-gp, HR 0.95, 95% CI 0.73–1.25; no P-gp, HR 0.99, 0.77–
1.28, interaction p-value 0.53).
Pharmacogenomic cohort study
Baseline characteristics. In total, there were 37,497 amoxicillin prescriptions from 8,513
unique individuals and 7,121 clarithromycin prescriptions from 5,031 unique individuals.
Patients who were prescribed clarithromycin were older (66.4 ± 12.4, [mean ± standard devia-
tion] versus 63.2 ± 13.2 versus years, SMD 0.246) and more likely to be male (3,959/7,121
prescriptions [55.6%] versus 17,549/37,497 [46.8%], SMD 0.177). Individuals prescribed clari-
thromycin were also more likely to have had a prior MI (933/7,121 [13.1%] versus 1,687/
37,497 [4.5%], SMD 0.307) and a history of COPD (2,135/7,121 [29.9%] versus 6,712/37,497
[17.9%], SMD 0.284). There was no significant difference in the percentage of patients with
diabetes (6,472/7,121 [90.9%] versus 33,822/37,497 [90.2%], SMD 0.024).
The numbers of prescriptions and unique individuals available for analysis stratified by
genotype are summarized in Table 4. The heterozygous (intermediate genetically predicted P-
gp activity) phenotype was most common for both SNPs. There were no significant differences
in prescribing of amoxicillin versus clarithromycin based on genotype.
Association between clarithromycin use and CV hospitalization stratified
by genetically predicted P-gp activity
Overall outcomes are summarized in Table 5. In total, there were 952 CV hospitalizations
within 1 year of antibiotic prescription in the clarithromycin group (13.3% of all clarithromy-
cin prescriptions) compared with 3,160 (8.4%) in the amoxicillin group. In this cohort, irre-
spective of genotype, clarithromycin prescription was associated with increased risk CV
hospitalization compared with amoxicillin at 15–30 days and 30 days to 1 year (crude HRs:
0–14 days 1.88; 95% CI 1.48–2.38, p< 0.001, 15–30 days 2.27; 95% CI 1.74–2.95, p< 0.001, 30
days–1 year 1.57; 95% CI 1.45–1.70, p< 0.001; adjusted HRs: 0–14 days 1.24; 95% CI 0.96–
1.60, p = 0.10, 15–30 days 1.50; 95% CI 1.14–1.99, p = 0.004, 30 days–1 year 1.10; 95% CI 1.01–
1.19, p = 0.027).
Table 4. Pharmacogenomic cohort population stratified by genotype and number of prescriptions.
Amoxicillin (n = 37,497) Clarithromycin (n = 7,121) p-value
rs1045642 0.29
High P-gp (GG) 7,995 (21.3) 1,575 (22.1)
Intermediate P-gp (GA) 18,156 (48.4) 3,433 (48.2)
Low P-gp (AA) 11,346 (30.3) 2,113 (29.7)
rs1128503 0.15
High P-gp (GG) 11,516 (30.7) 2,163 (30.3)
Intermediate P-gp (GA) 18,468 (49.3) 3,599 (50.4)
Low P-gp (AA) 7,513 (20.0) 1,373 (19.3)
�Allele dependent on genotyping platform used. P-gp, permeability-glycoprotein.
https://doi.org/10.1371/journal.pmed.1003372.t004
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When stratified by genotype, there was a significant gene-clarithromycin interaction for
risk of CV hospitalization at 30 days to 1 year. Individuals who were homozygous for the allele
associated with lower P-gp levels (AA) had significantly increased risk of CV hospitalization
between 30 days and 1 year when prescribed clarithromycin compared with amoxicillin
(rs1045642 AA: HR 1.39, 95% CI 1.20–1.60, p< 0.001, GG/GA: HR 0.99, 95% CI 0.89–1.10,
p = 0.85, interaction p-value < 0.001 and rs1128503 AA 1.41, 95% CI 1.18–1.70, p< 0.001,
GG/GA: HR 1.04, 95% CI 0.95–1.14, p = 0.43, interaction p-value< 0.001) (Table 6).
Restricting the analysis only to those individuals prescribed clarithromycin, for both the
rs1045642 and rs1128503 genetic variants, individuals with the AA genotype were more likely
to have a CV hospitalization between 30 days and 1 year than those with the GA or GG geno-
types (rs1045642: HR 1.34, 95% CI 1.15–1.56, p< 0.001; rs1128503: HR 1.22, 95% CI 1.02–
1.45, p = 0.025) (S2 Table).
Discussion
We performed a cohort study in 2 parts, combining a traditional epidemiological approach
with a pharmacogenomic study to evaluate the association of the use of the macrolide
Table 5. Cardiovascular events in the pharmacogenomic cohort study.
Total Number of Prescriptions CV Hospitalization
0–14 days 15–30 days 30 days to 1 year
Amoxicillin Total Number of Prescriptions 37,497 37,238 37,053
Number of Events (%) 259 (0.7) 185 (0.5) 2,716 (7.3)
Clarithromycin Total Number of Prescriptions 7,121 7,030 6,951
Number of Events (%) 91 (1.3) 79 (1.1) 782 (11.3)
https://doi.org/10.1371/journal.pmed.1003372.t005
Table 6. Association of clarithromycin and cardiovascular hospitalization (versus amoxicillin) stratified by P-glycoprotein genotype.
SNP rs1045642 rs1128503
Number of
events (%)
Crude
Hazard Ratio
Adjusted
Hazard Ratio
p-value Interaction p-
value
Number of
events (%)
Crude
Hazard Ratio
Adjusted
Hazard Ratio
p-value Interaction p-
value
0–14
days
0.49 0.66
GG/GA 243 (7.8) 2.07 (1.56–
2.73)
1.34 (0.99–1.82) 0.06 280 (7.8) 1.97 (1.52–
2.57)
1.31 (0.99–1.74) 0.06
AA 107 (8.0) 1.47 (0.93–
2.34)
1.03 (0.63–1.67) 0.92 70 (7.9) 1.50 (0.85–
2.65)
1.00 (0.54–1.84) 0.99
15–30
days
0.51 0.11
GG/GA 206 (6.7) 2.44 (1.82–
3.27)
1.54 (1.12–2.11) 0.008 234 (6.6) 2.11 (1.59–
2.81)
1.36 (1.00–1.84) 0.049
AA 58 (4.3) 1.72 (0.94–
3.13)
1.29 (0.69–2.42) 0.42 80 (3.4) 3.67 (1.77–
7.63)
2.77 (1.29–5.97) 0.009
30 days–
1 year
<0.001 <0.001
GG/GA 2,435 (7.9) 1.47 (1.33–
1.62)
0.99 (0.89–1.10) 0.85 2,830 (8.0) 1.50 (1.37–
1.64)
1.04 (0.95–1.14) 0.43
AA 1,062 (8.0) 1.81 (1.58–
2.08)
1.39 (1.20–1.60) <0.001 667 (7.6) 1.88 (1.58–
2.24)
1.41 (1.18–1.70) <0.001
AA, lowest genetically predicted P-glycoprotein levels; GA, intermediate genotype; GG, highest genetically predicted P-glycoprotein levels; SNP, single-nucleotide
polymorphism. Adjusted hazard ratio adjusted for age at prescription, sex, history of type 2 diabetes, myocardial infarction, and chronic obstructive pulmonary disease.
https://doi.org/10.1371/journal.pmed.1003372.t006
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antibiotic clarithromycin with CV risk. Our study has 2 key findings. First, not only was clari-
thromycin use associated with increased CV risk compared with amoxicillin, as other studies
have reported, but we have identified that the risk is particularly increased in those taking P-gp
inhibitors concurrently. This finding was strengthened by use of propensity-score weighting
to adjust the results, and a similar finding was observed in the observational analysis of the
genomic cohort. Second, in order to strengthen our findings, we have shown in a genomic
study (which should reduce the risk of confounding by indication) that the association of clari-
thromycin with CV hospitalization between 30 days and 1 year was significantly increased in
individuals with lower genetically predicted levels of P-gp activity. To the best of our knowl-
edge, this is the first time that such an approach has been used to examine this subject. These
results may suggest that, at least in part, the association of clarithromycin with increased CV
risk may be modified via P-gp and particular caution may be needed when prescribing clari-
thromycin in individuals taking P-gp inhibitors.
What this study adds to existing research
To the best of our knowledge, our study is the first to specifically examine a treatment interac-
tion with P-gp inhibitors and substrates. Although clarithromycin is commonly recognized as
a P-gp inhibitor [18], it is also a substrate for P-gp, and intracellular levels are increased when
another P-gp inhibitor is co-administered [34, 35]. Supporting this, in our genomic analysis,
we found that individuals with lower genetically predicted P-gp activity had a higher risk of
CV hospitalization between 30 days and 1 year of clarithromycin prescription. Because of the
random allocation of genotype at birth, pharmacogenomic studies are less likely to be affected
by indication bias than traditional observational studies [36]. In a traditional observational
study, this might account for an increase in CV risk seen with P-gp use. There was a higher
crude number of events in the amoxicillin group than those prescribed clarithromycin
(Table 2); however, after propensity-score adjustment, clarithromycin prescription was associ-
ated with worse outcome. This has been previously reported and is because patients prescribed
amoxicillin alone tend to be older and more unwell; hence, methods such as propensity-score
weighting are required to account for this [37], and this is likely to contribute to the nonsignifi-
cant unadjusted increase in mortality seen with amoxicillin in our study.
Concerns regarding the CV risk of macrolide antibiotics have been present for several years
[38] and were strengthened by the results of the CLARICOR randomized trial, which, contrary
to the authors’ original hypothesis, demonstrated an increased risk of CV mortality at both 3
and 10 years [4, 16]. These results have been further supported by several large observational
studies [5–7, 39] and meta-analyses [9, 10], which have reported increased CV risk of myocar-
dial infarction and CV hospitalization up to 1 year after macrolide prescription. Other macro-
lides such as azithromycin have also been linked with increased CV risk [8]. Nevertheless,
there have been alternative large observational studies that have suggested that there is no sig-
nificantly increased CV risk with macrolide use [13, 14]. These alternative results suggest that
there may be specific patient groups who are at particular risk when prescribed clarithromycin.
The mechanism of increased CV risk with clarithromycin is not completely clear. The short-
term increased risk of sudden cardiac death has been attributed to the effect of macrolides on
the QT interval leading to arrhythmia, but this does not explain the increased long-term CV
risk observed in CLARICOR and other studies that persisted after drug discontinuation. Alter-
native theories include macrophage activation leading to coronary plaque destabilization and
acute coronary syndrome [40]. With these proposed mechanisms, any pathway by which
metabolism of clarithromycin is impaired might lead to increased CV risk. Most studies have
so far focused on the CYP3A4 enzyme; however, the interaction with macrolides has not been
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consistent [6, 35]. We also did not find a significant interaction between clarithromycin and
CYP3A4 inhibition.
Strengths and limitations
The key strength of our study is our use of both inverse probability of treatment weighting in
our longitudinal cohort and a pharmacogenomic study. By using both of these methods, we
strengthen the evidence supporting our finding that the increase in CV risk following clari-
thromycin prescription is associated with P-gp. Our study has some limitations. First, there are
inherent limitations with any observational study, although our use of propensity weighting
for likelihood of prescription and genomics do obviate some of these. Nevertheless, it is possi-
ble that unmeasured confounding could affect our results. Second, our pharmacogenomic
cohort was mainly white, and further studies are required to determine whether our findings
in this group are applicable to other ethnicities. As there have been no large genome-wide asso-
ciation studies looking at P-gp activity, we were unable to construct a weighted genetic risk
score to evaluate the cumulative effect of P-gp SNPs. A large genome-wide association study
would provide more precision around the effect of genetic variants. We used electronic health
records and ICD coding to determine prescribing and outcomes; thus, we could not determine
adherence. We could also not robustly ascertain prescribing indication and adjust for this,
although the majority of prescriptions are likely to have been for suspected lower respiratory
tract infection. Nevertheless, current coding accuracy in Scotland is considered reliable [41–
43]. Furthermore, any inconsistency would affect both clarithromycin and amoxicillin cohorts
equally. We used amoxicillin as a comparator as it is the most-commonly prescribed antibiotic
for this indication in the UK, and we did not evaluate other antibiotic classes. We did not have
any allergy information, which might also provide another source of indication bias.
Clinical implications and next steps
Macrolides are primarily used to treat respiratory infections; however, alternatives such as
amoxicillin or tetracyclines are not associated with increased CV risk, are not metabolized
through P-glycoprotein, and have been shown in randomized trials to be noninferior to treat-
ment regimens including macrolides [44, 45]. The most recent American Thoracic Society
guidelines for community-acquired pneumonia recommend the use of macrolide monother-
apy only in areas where macrolide resistance is low and in patients in whom alternative antibi-
otics are contraindicated [46]. Given that drugs such as calcium channel blockers are widely
used (in 1 cohort, concurrently prescribed in up to 20% of patients with respiratory infections)
[8] and such patients may already be at increased CV risk because of their underlying drug
indication, advice to be cautious with clarithromycin seems justified as there are equally effica-
cious alternatives that do not carry this increased risk. This is consistent with advice from the
US FDA that proposes caution with clarithromycin use in those with increased CV risk. Our
study heralds the possibility of “precision” prescribing, in which patients are prescribed alter-
native antibiotics if they are taking P-gp inhibitors or if they have a particular genotype. Recent
work has suggested the potential for P-gp-associated SNPs to be used in pharmacogenomic
strategies for prescribing in other settings [47]. Mechanistic studies evaluating the pathophysi-
ology of P-gp-associated gene and drug interactions in detail would further our understanding
and inform future clinical practice.
Conclusion
We found that clarithromycin use was associated with an increased risk of CV hospitalization
up to 1 year post-prescription compared with amoxicillin. There appears to be an effect
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modification via P-gp, with a particularly increased risk of adverse CV events with clarithro-
mycin in patients also taking drugs that are P-gp substrates or those with lower genetically pre-
dicted levels of P-gp activity.
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